Minimal Residual Disease Testing: A New Way Forward

There are two important news items to report this week.  First, an article in Blood reports that current MRD testing for myeloma in the US is producing quite erratic results.

In Cancer Research, Big Data Needs to Be Smart, Too

The University of Texas MD Anderson Cancer Center has announced that it will partner with IBM's Watson supercomputer to fight cancer - specifically leukemia. But myeloma patients may well ask:  "What can Big Data do for me?" The answer is: "A lot." 
 

Understanding the Body's Immune Defenses Against Myeloma

A recent article in the New York Times draws attention to how cancers survive and evade the immune system and highlights a new book, "The Compatibility Gene: How Our Bodies Fight Disease."  The key point for myeloma research is that inactivation of T-lymphocyte cells and natural killer cells--which should be killing myeloma cells--occurs through a mechanism called the PD-1/PD-L1 system.
 

Matching Resources with Stratified Recommendations for Myeloma Care

Two recent publications highlight the need to adapt guidelines to accommodate treatment that is truly available in different countries and regions of the world.

Black Swan Research Initiative's Distinctively Different Pathway to a Cure

Earlier this year the IMF launched the Black Swan Research Initiative, a breakthrough approach to finding a cure for myeloma. Following in our footsteps, others are ramping up their myeloma research efforts. This is great news for myeloma patients, and in science it's particularly useful to have lots of people examining data in different ways.

Pages